Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. (2021)
Attributed to:
Regulatory T cell therapy for IBD
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2021-324789
PubMed Identifier: 33903149
Publication URI: http://europepmc.org/abstract/MED/33903149
Type: Journal Article/Review
Volume: 70
Parent Publication: Gut
Issue: 10
ISSN: 0017-5749